References
- Wright G. Antibiotics: an irresistible newcomer. Nature. 2015;517(7535):442–444.
- Ling LL, Schneider T, Peoples AJ, et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015;517(7535):455–459.
- Mandalapu D, Ji X, Chen J, et al. Thioesterase-mediated synthesis of teixobactin analogues: mechanism and Substrate Specificity. J Org Chem. 2018;83:7271–7275.
- Parmar A, Lakshminarayanan R, Iyer A, et al. Design and syntheses of highly potent teixobactin analogues against staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus (MRSA), and Vancomycin-Resistant Enterococci (VRE) in vitro and in vivo. J Med Chem. 2018;61(5):2009–2017.
- Singh I. Simplified teixobactin analogues to target superbugs. Future Med Chem. 2018;10(2):133–134.
- Piddock LJ. Teixobactin, the first of a new class of antibiotics discovered by iChip technology? J Antimicrob Chemother. 2015;70(10):2679–2680.
- Fujita T, Fujii H. Efficient isolation of specific genomic regions retaining molecular interactions by the iChIP system using recombinant exogenous DNA-binding proteins. BMC Mol Biol. 2014;15:26.
- Nichols D, Cahoon N, Trakhtenberg EM, et al. Use of ichip for high-throughput in situ cultivation of “uncultivable” microbial species. Appl Environ Microbiol. 2010;76(8):2445–2450.
- Banerjee D, Chakraborty B. Anthrax: where margins are merging between emerging threats and bioterrorism. Indian J Dermatol. 2017;62(5):456–458.
- Lowy FD. Methicillin-resistant Staphylococcus aureus: where is it coming from and where is it going? JAMA Intern Med. 2013;173(21):1978–1979.
- Boswihi SS, Udo EE, Monecke S, et al. Emerging variants of methicillin-resistant Staphylococcus aureus genotypes in Kuwait hospitals. PLoS One. 2018;13(4):e0195933.
- Huang SH, Chen YC, Chuang YC, et al. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012–2013. J Microbiol Immunol Infect. 2016;49(5):701–707.
- Jin K, Sam IH, Po KH, et al. Total synthesis of teixobactin. Nat Commun. 2016;7:12394.
- Lee W, Schaefer K, Qiao Y, et al. The mechanism of action of lysobactin. J Am Chem Soc. 2016;138(1):100–103.
- Ng V, Chan WC. New found hope for antibiotic discovery: lipid II inhibitors. Chemistry. 2016;22(36):12606–12616.
- Oppedijk SF, Martin NI, Breukink E. Hit ‘em where it hurts: the growing and structurally diverse family of peptides that target lipid-II. Biochim Biophys Acta. 2016;1858(5):947–957.
- Parmar A, Iyer A, Vincent CS, et al. Efficient total syntheses and biological activities of two teixobactin analogues. Chem Commun (Camb). 2016;52(36):6060–6063.
- Jad YE, Acosta GA, Naicker T, et al. Synthesis and biological evaluation of a teixobactin analogue. Org Lett. 2015;17(24):6182–6185.
- Malkawi R, Iyer A, Parmar A, et al. Cysteines and disulfide-bridged macrocyclic mimics of teixobactin analogues and their antibacterial activity evaluation against methicillin-resistant. Pharmaceutics. 2018;10(4):183.
- Zong Y, Sun X, Gao H, et al. Developing equipotent teixobactin analogues against drug-resistant bacteria and discovering a hydrophobic interaction between lipid II and teixobactin. J Med Chem. 2018;61(8):3409–3421.
- Wen PC, Vanegas JM, Rempe SB, et al. Probing key elements of teixobactin-lipid II interactions in membranes. Chem Sci. 2018;9(34):6997–7008.
- Sertkaya A, Wong HH, Jessup A, et al. Key cost drivers of pharmaceutical clinical trials in the United States. Clin Trials. 2016;13(2):117–126.
- [cited 2018 Oct 1] Available from: http://www.themedicinescompany.com/investors/news/medicines-company-announces-tango-2-trial-meropenem-vaborbactam-formerly-carbavance
- Hover BM, Kim SH, Katz M, et al. Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant gram-positive pathogens. Nat Microbiol. 2018;3(4):415–422.
- Ramchuran EJ, Somboro AM, Abdel Monaim SAH, et al. Antibacterial activity of teixobactin derivatives on clinically relevant bacterial isolates. Front Microbiol. 2018;9:1535.
- Ng V, Kuehne SA, Chan WC. Rational design and synthesis of modified teixobactin analogues: in vitro antibacterial activity against Staphylococcus aureus, propionibacterium acnes and pseudomonas aeruginosa. Chemistry. 2018;24(36):9136–9147.